This is a working overview of aggregation, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-09 and is reviewed periodically as new material appears.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
are reference values for the pressure and density fields respectively). Since both the solutions belong to the class of Beltrami flow, the vorticity field is parallel to the velocity and, for the case with positive helicity, is given by
As the Southern Operations Room advanced in the suburbs of Damascus, the Syrian Free Army was reported closing in on the capital from the north, after taking control of Palmyra, as well as Darayya. The Republican Guard, traditionally tasked with protecting the Syrian government, did not organize any defenses of Damascus and offered no resistance to the rebel advances. According to The Guardian, videos showed Syrian police and army forces removing their uniforms in the streets of Damascus and an Associated Press journalist reported seeing armed residents along the roads in Damascus's outskirts and finding the city's main police headquarters abandoned. Tank movements were reported in central squares of the capital, while calls of "God is great" rang out from mosques. Even as the situation in Damascus deteriorated, Assad reportedly pretended to work as usual, though he made no effort to organize a last stand or publicly inspire confidence among his loyalists. Syrian state media officially denied allegations that he had fled the capital. In the evening, Assad met with thirty army and security chiefs at the Ministry of Defense, and urged them to keep resisting the insurgents as Russian support was on its way. At 10:30 pm, the president received a phone call by his prime minister Mohammad Ghazi al-Jalali who informed him that the government's situation had further declined, with large numbers of refugees fleeing from Homs toward Latakia. Assad just told him "Tomorrow, we will see. Tomorrow, tomorrow," ending the call.
In pharmaceutical industry, stability testing is a process that is used to determine the quality of a drug substance or drug product over a period of specified time under specific environmental conditions. With stability testing, pharmaceutical industry inspects the quality of drug substances and drug products as per the guidelines outlined by US Food and Drug Administration and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use to make sure that they retained the quality over the period of time. Stability testing depends upon the environmental factors like, light source, humidity and ambient temperature as well as the physical and chemical properties of the active drug product.
Sources: en.wikipedia.org
The subject of marriage for Rhaenyra is a hot topic ; Viserys dismisses Lord Jason Lannister's marriage proposal, Otto proposes betrothing Rhaenyra to Aegon, and Master of Laws Lord Lyonel Strong proposes betrothing Rhaenyra with Corlys' son Ser Laenor Velaryon. After the hunt, Viserys assures Rhaenyra that he will not replace her as his heir, and encourages her to find a husband who can strengthen her claim to the throne. He refuses to send reinforcements to the forces of Corlys and Daemon in the Stepstones, refusing to aid his brother after his previous actions. Daemon returns from a victorious campaign in the Stepstones, and swears his allegiance to Viserys by handing him his crown from the Stepstones. Though the two celebrate their reunion at a feast, their relationship dissolves again when Viserys is informed by Otto that Daemon seduced Rhaenyra in King's Landing, which also makes Viserys angry at Otto for spying on Rhaenyra. A drunk Daemon confirms their affair and proposes marriage to Rhaenyra, influencing Viserys to exile Daemon again and accuse him of wanting his crown. Viserys betrothes Rhaenyra to Laenor to avoid scandal and stabize relations with House Velaryon, which she accepts on the condition that he remove Otto as his Hand for spying on her and having greater personal ambitions. Viserys sends Otto back to Oldtown, and gives Rhaenyra a drink to prevent pregnancy from her affair. Viserys and Rhaenyra travel to Driftmark to propose the union of Rhaenyra and Laenor, which Corlys and Rhaenys gladly accept.
== Bacterial cellulose-based textiles == Unlike plant-derived cellulose, bacterial cellulose offers superior mechanical properties, such as high tensile strength and flexibility, making it an attractive option for a wide range of textile applications. Moreover, the cultivation of bacterial cellulose can be achieved using simple fermentation processes, minimizing the environmental footprint associated with traditional textile manufacturing. Yeast, fungi and algae species including: the bacterium Pseudomonas fluorescens, the yeast Yarrowia lipolytica, the sponge Acanthella elongata, the algae Stoechospermum marginatum, and the fungus Candida albicans have all been researched for their ability to be used on substrates to create natural composites for biotextiles.
== Outcomes and impact == The programme has been associated with improved child nutrition, increased milk consumption, and greater awareness of dairy’s benefits among Thai children. Economically, it stabilizes the dairy sector by guaranteeing a domestic market for local producers, accounting for more than 30 percent of Thailand’s liquid milk sales.
Sources: en.wikipedia.org
== History == In the 19th century, the mass-to-charge ratios of some ions were measured by electrochemical methods. The first attempt to measure the mass-to-charge ratio of cathode ray particles, assuming them to be ions, was made in 1884-1890 by German-born British physicist Arthur Schuster. He put an upper limit of 10^10 coul/kg, but even that resulted in much greater value than expected, so little credence was given to his calculations at the time. In 1897, the mass-to-charge ratio of the electron was first measured by J. J. Thomson. By doing this, he showed that the electron was in fact a particle with a mass and a charge, and that its mass-to-charge ratio was much smaller than that of the hydrogen ion H+. In 1898, Wilhelm Wien separated ions (canal rays) according to their mass-to-charge ratio with an ion optical device with superimposed electric and magnetic fields (Wien filter). In 1901 Walter Kaufman measured the increase of electromagnetic mass of fast electrons (Kaufmann–Bucherer–Neumann experiments), or relativistic mass increase in modern terms. In 1913, Thomson measured the mass-to-charge ratio of ions with an instrument he called a parabola spectrograph. Today, an instrument that measures the mass-to-charge ratio of charged particles is called a mass spectrometer.
The vacuum flask consists of two vessels, one placed within the other and joined at the neck. The gap between the two vessels is partially evacuated of air, creating a partial-vacuum which reduces heat conduction or convection. Heat transfer by thermal radiation may be minimized by silvering flask surfaces facing the gap but can become problematic if the flask's contents or surroundings are very hot; hence vacuum flasks usually hold contents below the boiling point of water. Most heat transfer occurs through the neck and opening of the flask, where there is no vacuum. Vacuum flasks are usually made of metal, borosilicate glass, foam or plastic and have their opening stoppered with cork or polyethylene plastic. Vacuum flasks are often used as insulated shipping containers. Extremely large or long vacuum flasks sometimes cannot fully support the inner flask from the neck alone, so additional support is provided by spacers between the interior and exterior shell. These spacers act as a thermal bridge and partially reduce the insulating properties of the flask around the area where the spacer contacts the interior surface. Several technological applications, such as NMR and MRI machines, rely on the use of double vacuum flasks. These flasks have two vacuum sections. The inner flask contains liquid helium and the outer flask contains liquid nitrogen, with one vacuum section in between. The loss of precious helium is limited in this way.
=== Infrared ear thermometers === Diatek Corporation and NASA developed an aural thermometer that measures the thermal radiation emitted by the eardrum, similar to the way the temperature of stars and planets are measured. This method avoids contact with mucous membranes and permits rapid temperature measurement of newborn or incapacitated patients. NASA supported the Diatek Corporation through the Technology Affiliates Program.
Each medal has a portrait of Alfred Nobel in left profile on the obverse. The medals for Chemistry, Literature, Physics, and Physiology or Medicine have identical obverses, showing the image of Nobel and the years of his birth and death. Nobel's portrait also appears on the obverse of the Peace Prize medal and the Economics Prize medal, but with a slightly different portrait. The names of the chemistry, medicine, literature and physics prize recipients are engraved on the reverse of the medal on a small plate. The names of the peace and economic prize recipients are engraved on the edges of their medals. The Chemistry, Literature, Physics, and Physiology or Medicine medals were designed by Erik Lindberg. The Peace prize medal was designed by Gustav Vigeland, and the Economics prize medal by Gunvor Svensson-Lundqvist. The inaugural Nobel laureates of 1901 received a 'temporary' medal that was struck in a lesser metal than gold. The first medals were eventually struck in September 1902. The delay was due to the designs needing to be approved by each respective awarding institution. The medals were designed by the sculptor Erik Lindberg. Between 1902 and 2010 the Nobel Prize medals were struck by the Myntverket, the Swedish royal mint, located in Eskilstuna. In 2011 the medals were made by Det Norske Myntverket in Kongsberg. The medals have been made by Svenska Medalj in Eskilstuna since 2012 with the exception of the peace prize medal which is made by the Det Norske Myntverket.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.